Skip to Main Content

VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX20-121-103

Conditions

Diseases of the Endocrine System | Genetics - Adult | Genetics - Pediatric

Phase III

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation.

  • Trial with
    Vertex Pharmaceuticals Incorporated
  • Start Date
    12/16/2021
  • End Date
    07/31/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/09/2022
  • Study HIC
    #2000030926